●屡获教育部科技进步二等奖、上海市科技进步二等奖、AHA Paul Dudley White最佳研究奖、ESC 血管生物学学组最佳研究奖等 参考文献: [1].SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction. ESC 2024. [2]. 中华医学会心血管病学分会,中国医师协会心血管内科医...
医学博士Jonathan Rich将总结SGLT2抑制剂在心力衰竭患者专门试验中的效果。 Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors JACC: Heart Failurearticle Early Recent, June 01, 202...
SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure (HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive. This article discusses the current clinical evidence for using SGLT2i in different types of heart failure and provides an overview ...
参考文献 1.Borlaug BA, Testani JM. SGLT2 inhibitors and diuretics in heart failure: clicking reset on the renal volume setpoint? Eur Heart J. 2023 Aug 14;44(31):2944-2946. doi: 10.1093/eurheartj/ehad345. PMID: 3...
[10]. Velliou M, Polyzogopoulou E, Ventoulis I, Parissis J. Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Rev Clin Pharmacol. 2023 Feb;16(2):149-160. [11]. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart...
[1]Arjun K. Pandey, Deepak L. Bhatt, Avinash Pandey, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. European Heart Journal (2023) 44, 3640–3651 https://doi.org/10.1093/eurheartj/ehad389. ...
该Meta分析包含5项相关研究（EMPEROR- PRESERVED、VERTIS-CV、DECLARE-TIMI 58、SOLOIST-WHF、SCORED）、9726例舒张性心衰患者，其中5046例接受SGLT2i治疗，4680例应用安慰剂。来源：[1]Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-...
[1]Milton Packer. Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure. Nature Reviews Cardiology, 2022, 19: 499–500. [2]江耀辉,王喆,郑汝杰,等.达格列净对冠心病合并2型糖尿病患者临床结局的影响.中国循环杂志, 2022, 37: 250-255. DOI: 10.3969/j.issn.1000-361...
Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemi...
SGLT-2 inhibitorsType 2 diabetescardiovascular outcomeheart failure hospitalizationHeart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce hospitalization due to heart failure (hHF). While ...